CSIMarket
 
Kymera Therapeutics Inc   (KYMR)
Other Ticker:  
 
 
Price: $35.1200 $1.36 4.028%
Day's High: $35.57 Week Perf: -1.29 %
Day's Low: $ 33.67 30 Day Perf: -13.45 %
Volume (M): 620 52 Wk High: $ 45.31
Volume (M$): $ 21,764 52 Wk Avg: $25.65
Open: $33.67 52 Wk Low: $9.60



 Market Capitalization (Millions $) 2,052
 Shares Outstanding (Millions) 58
 Employees -
 Revenues (TTM) (Millions $) 40
 Net Income (TTM) (Millions $) -176
 Cash Flow (TTM) (Millions $) 91
 Capital Exp. (TTM) (Millions $) 24

Kymera Therapeutics Inc
Kymera Therapeutics Inc is a biotechnology company based in Cambridge, Massachusetts. It focuses on developing targeted protein degradation therapies to address various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. The company's proprietary platform enables the selective degradation of disease-causing proteins, providing a novel approach to drug development. By harnessing the body's natural protein degradation system, Kymera aims to create highly specific and effective treatments for previously challenging conditions.


   Company Address: 200 Arsenal Yards Blvd Watertown 2472 MA
   Company Phone Number: 285-5300   Stock Exchange / Ticker: NASDAQ KYMR
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Disruptive Therapies: Kymera's Strategic Advancements in Cancer and Dermatitis Treatment Swaying the Course of Drug Discovery

Published Mon, Apr 8 2024 11:00 AM UTC

Pioneering new therapeutic paradigms, Kymera Therapeutics has lately revealed fascinating compositional studies and significant clinical advancements, significantly shaping its credibility in the biomedical field. The company?s revelations were embedded in their scientific presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting, as well as in...

Product Service News

Unleashing the Power of Oral Small Molecule Degraders: Kymera Therapeutics' Journey towards Biologics-Like Activity in Immunology

Published Fri, Mar 8 2024 3:00 PM UTC

Advancing Oral Small Molecule Degraders in Immunology: A Promising Approach to Biologics-Like ActivityIn recent years, the field of drug development has witnessed significant advancements in the pursuit of novel therapeutics. Specifically, the emergence of targeted protein degradation as a therapeutic approach has garnered immense attention. Kymera Therapeutics, a leading co...

Shares

Kymera Therapeutics Raises $275 Million in Public Offering to Fuel Advancement of Targeted Protein Degradation Therapies

Published Tue, Jan 9 2024 2:15 PM UTC

Kymera Therapeutics Successfully Closes Upsized Public Offering, Raising $275 Million to Advance Targeted Protein Degradation Therapies
WATERTOWN, Mass., Jan. 09, 2024 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company pioneering the development of small molecule medicines through targeted protein degradation (TPD), has announced the s...

Management Announcement

Kymera Therapeutics: Pioneering Innovation and Progress in Immunology and Oncology for 2024 and Beyond

Published Tue, Jan 9 2024 2:17 PM UTC



In a groundbreaking move, Kymera Therapeutics, a leading biotechnology company, has laid out its key objectives and strategic vision for the year 2024. Combining innovative science with a patient-centric approach, Kymera aims to advance its portfolio of Immunology and Oncology programs. The company's recent announcement of the expected completion of enrollment and ...

Management Announcement

Kymera Therapeutics Raises $275 Million in Successful Public Offering, Cementing Position as Leader in Targeted Protein Degradation

Published Fri, Jan 5 2024 11:00 AM UTC

Kymera Therapeutics Announces Successful Pricing of $275 Million Public Offering, Setting the Stage for Continued Progress in Targeted Protein Degradation
WATERTOWN, Mass., January 5, 2024 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a pioneering clinical-stage biopharmaceutical company leveraging targeted protein degradation (TPD) to develop a new class of small molecule...






 

Kymera Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com